We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-1.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$67.6M
AUM Growth
-$6.2M
Cap. Flow
-$3.41M
Cap. Flow %
-5.05%
Top 10 Hldgs %
57.93%
Holding
76
New
1
Increased
16
Reduced
1
Closed
13
Avg Time Held Equity + Options
1.7 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
1.2 years
Avg Time Held Equity only
1.8 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
1.3 years

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$259K
2
SRPT icon
Sarepta Therapeutics
SRPT
+$255K
3
EXAS icon
Exact Sciences
EXAS
+$246K
4
NKTR icon
Nektar Therapeutics
NKTR
+$73.7K
5
LGND icon
Ligand Pharmaceuticals
LGND
+$43.2K

Top Sells

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$506K
2
CLLS icon
Cellectis
CLLS
+$409K
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$408K
4
RUBY
Rubius Therapeutics, Inc
RUBY
+$391K
5
WVE icon
Wave Life Sciences
WVE
+$377K

Sector Composition

Rank Sector Weight
1 Healthcare 58.79%
2 Miscellaneous 41.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RUBY
76
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-21,610
Closed -$391K –
1 2 3
4

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2019 Portfolio in Review

As of Q2 2019, Opus Point Partners Management held 76 positions worth $67.6M, down 8.4% from $73.8M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Opus Point Partners Management withdrew a net $3.41M in Q2 2019, closing 13 positions and reducing 1 holding. Its most notable exit was Regenxbio, an estimated $506K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 60% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in Biogen worth $263K.

  • Opus Point Partners Management's largest Q2 2019 buy was Biogen: 1,123 shares worth $263K.
  • Opus Point Partners Management added most to Sarepta Therapeutics in Q2 2019, an estimated $255K increase.
  • Opus Point Partners Management's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $274K.
  • Opus Point Partners Management fully exited Regenxbio in Q2 2019, selling an estimated $506K.
  • Opus Point Partners Management's ten largest holdings make up 58% of its $67.6M portfolio in Q2 2019.
  • Opus Point Partners Management opened 1 new position and closed 13 in Q2 2019.
  • Opus Point Partners Management's portfolio value fell 8.4% quarter-over-quarter to $67.6M.

Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.